In the US market, Dr. Reddy's introduces generic Revlimid
In order to resolve all outstanding claims in its lawsuit, Celgene, the company that makes Revlimid, consented to provide Dr. Reddy's a licence to distribute volume-restricted quantities of generic lenalidomide capsules in the US.
admin
Lenalidomide Capsules, a therapeutically similar generic form of Revlimid (lenalidomide) Capsules that has been approved by the US Food and Drug Administration (USFDA) for the US market, have been introduced by Dr. Reddy's Laboratories Ltd.
According to a press release from the city-based pharmaceutical company, Dr. Reddy's is qualified for first-to-market, 180-days of generic medication exclusivity for Lenalidomide Capsules in 2.5 mg and 20 mg strengths with this volume-limited launch. The medication is used to treat a number of cancer types.
"We are happy to announce that two of our six strengths of Lenalidomide Capsules have been launched first-to-market with a 180-day market exclusivity. Greater patient access to this critical medication is made possible by the release of a more cheap generic version on the market "According to Dr. Reddy's, North America Generics CEO Marc Kikuchi.
As previously reported, Celgene, the company that makes Revlimid, consented to provide Dr. Reddy's a licence to market volume-restricted quantities of generic lenalidomide capsules in the US as payment for all unresolved claims in its legal action.
The percentages that were agreed upon are kept private. In accordance with the settlement, Dr. Reddy's has also been granted permission to start selling generic lenalidomide capsules in the US on January 31, 2026, without any volume restrictions.
There are 28-count bottle sizes of the 2.5 mg, 5 mg, and 10 mg strengths of Dr. Reddy's Lenalidomide Capsules as well as 21-count bottle sizes of the 15 mg, 20 mg, and 25 mg strengths.
